palbociclib (Q15269707)

From Wikidata
Jump to: navigation, search
drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer
  • Ibrance®
  • PD-0332991
  • PD0332991
  • 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
  • PD 332991
  • UNII-G9ZF61LE7G
  • PD 0332991
edit
Language Label Description Also known as
English
palbociclib
drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer
  • Ibrance®
  • PD-0332991
  • PD0332991
  • 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
  • PD 332991
  • UNII-G9ZF61LE7G
  • PD 0332991

Statements

447.238±0 atomic mass unit
1 reference
C₂₄H₂₉N₇O₂
1 reference
CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
1 reference

Identifiers

1 reference
10219048
1 reference
 
edit
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit